Mycobacterium Abscessus Infection – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Mycobacterium Abscessus Infection Market Outlook

Thelansis’s “Mycobacterium Abscessus Infection Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Mycobacterium Abscessus Infection treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Mycobacterium Abscessus Infection Overview

Mycobacterium abscessus infection is a rare but clinically significant disease caused by a rapidly growing nontuberculous mycobacterium (NTM) that is notoriously resistant to many antibiotics. It most often affects the lungs, particularly in individuals with underlying conditions such as cystic fibrosis or chronic lung disease, but can also involve the skin, soft tissues, and post‑surgical sites. Patients typically present with chronic cough, sputum production, fatigue, and sometimes systemic symptoms, while cutaneous infections may appear as nodules, abscesses, or non‑healing wounds. Diagnosis requires culture and molecular testing to confirm species identification and drug resistance patterns. Treatment is challenging, often requiring prolonged multidrug regimens that combine macrolides with intravenous agents such as amikacin, imipenem, or tigecycline, yet relapse and treatment failure are common. Because of its multidrug resistance, clinical variability, and association with vulnerable patient populations, M. abscessus infection is considered one of the most difficult NTMs to manage, highlighting the urgent need for new therapeutic strategies and improved infection control measures.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Mycobacterium Abscessus Infection – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035